Clobetasol propionate is a corticosteroid used to treat skin conditions such as eczema, contact dermatitis, seborrheic dermatitis, steroid responsive dermatosis, and psoriasis. It is a superpotent topical glucocorticoid that binds the glucocorticoid receptor to reduce inflammation, suppress immune cell activity in the skin, decrease cytokine release, and produce local vasoconstriction. Chemically it is a synthetic fluorinated corticosteroid with an empirical formula C25H32ClFO5 and a molecular weight near 467 g/mol. Physicochemical properties include a white to off-white crystalline appearance and low aqueous solubility with good solubility in common organic solvents used for topical formulation. Typical commercial products contain 0.05 percent active drug in vehicles designed for cutaneous delivery and it is applied to the skin as a cream, foam, gel, liquid, solution, oin. For formulators and clinicians relevant points include potent antiinflammatory activity at low concentrations, limited systemic absorption when used as directed on intact skin, increased percutaneous absorption under occlusion, and common formulation strategies to optimize local retention while minimizing systemic exposure.
Parent: Clobetasol
Parent: Clobetasol Propionate
The active substance is controlled to pharmaceutical quality levels consistent with ICH and pharmacopeial expectations. Typical specifications control related compounds and degradation products using validated chromatographic methods; reporting and identification are commonly aligned with ICH Q3A thresholds (reporting threshold approximately 0.05 percent, identification at approximately 0.10 percent, and qualification considerations beginning near 0.15 percent, depending on maximum daily exposure). In finished API specifications, individual specified related compounds are often limited to not more than 0.1 to 0.2 percent each and total impurities are typically limited to about 0.5 to 1.0 percent, with tighter limits applied to known toxicologically relevant degradants as appropriate. Common classes of related substances monitored include stereoisomeric epimers, deesterified or hydrolysis products, oxidation products and dehalogenation products; residual solvents and elemental impurities are controlled to ICH Q3C and Q3D limits respectively.
Clobetasol propionate is used topically to treat inflammatory and immune mediated dermatoses where a superpotent corticosteroid is indicated, for example severe eczema, resistant contact dermatitis, seborrheic dermatitis, steroid responsive dermatoses and plaque psoriasis, to reduce inflammation, itching and scaling.
Clobetasol propionate is not a treatment for acne; because it is a potent corticosteroid, its use on acneiform conditions can worsen acneiform eruptions, cause steroid induced rosacea or promote skin atrophy, so corticosteroids are generally avoided for primary acne therapy.
Clobetasol should not be used on the face, groin or intertriginous areas for prolonged periods, on open or infected wounds unless directed by a clinician, or over large body surface areas or broken skin without medical supervision due to increased risk of systemic absorption and local adverse effects.
No, clobetasol is a corticosteroid and has no intrinsic antifungal activity; using it alone on fungal infections can mask symptoms and allow fungal proliferation, so antifungal agents are required when a fungal etiology is present.
